1
|
Mohammadi F, Mohsenpour MA, Sohrabi Z, Niakousari M, Jeddi M, Hassanzadeh J, Ferns GA, Eftekhari MH. The effects of powdered drinks enriched with curcumin and probiotics on lipid profile and atherogenic indices in patients with metabolic syndrome: A randomized, double-blinded, placebo-controlled clinical trial. Food Sci Nutr 2024; 12:1257-1267. [PMID: 38370069 PMCID: PMC10867475 DOI: 10.1002/fsn3.3839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 10/27/2023] [Accepted: 11/03/2023] [Indexed: 02/20/2024] Open
Abstract
Cardiovascular disease is prevalent globally and is the most common complication of metabolic syndrome (MetS). Previous studies have suggested that curcumin and probiotics may improve the lipid profile, so we aimed to investigate the effects of the edible powder enriched with these substances on lipid profile level and atherogenic indices such as Atherogenic Coefficient (AC), Castelli Risk Index-I (CRI-I), Castelli Risk Index-II (CRI-II), and Atherogenic Index of Plasma (AIP). In the present parallel randomized double-blinded placebo-controlled clinical trial, 124 people with MetS with overweight or obesity were randomly allocated to 4 groups and were followed up for 8 weeks. The participants received a low-calorie diet and a daily sachet of enriched powder drink. The sachets contained either 109 CFU of probiotics or 1 g of curcumin, or probiotic + curcumin (pro + cur), or placebo, respectively. The fasting lipid profile and atherogenic indices were measured at the beginning and end of the study. One hundred and fourteen participants completed the study. At the end of the study, the within- and between-group comparisons showed no significant differences in lipid profile and atherogenic indices (p > .05). Based on the results of the current study, taking an oral powder containing 1 g curcumin and 109 CFU probiotics for 8 weeks had no effect on the lipid profile level and atherogenic indices; however, more studies are recommended.
Collapse
Affiliation(s)
- Farzaneh Mohammadi
- Department of Clinical Nutrition, School of Nutrition and Food SciencesShiraz University of Medical SciencesShirazIran
- Student Research Committee, School of Nutrition and Food SciencesShiraz University of Medical SciencesShirazIran
| | - Mohammad Ali Mohsenpour
- Department of Clinical Nutrition, School of Nutrition and Food SciencesShiraz University of Medical SciencesShirazIran
- Student Research Committee, School of Nutrition and Food SciencesShiraz University of Medical SciencesShirazIran
| | - Zahra Sohrabi
- Nutrition Research Center, School of Nutrition and Food SciencesShiraz University of Medical SciencesShirazIran
| | - Mehrdad Niakousari
- Department of Food Science and Technology, College of AgricultureShiraz UniversityShirazIran
| | - Marjan Jeddi
- Endocrinology and Metabolism Research CenterShiraz University of Medical SciencesShirazIran
| | - Jafar Hassanzadeh
- Department of Epidemiology, School of Health, Research Center for Health Sciences, Institute of HealthShiraz University of Medical SciencesShirazIran
| | - Gordon A. Ferns
- Department of Medical EducationBrighton & Sussex Medical SchoolBrightonUK
| | - Mohammad Hassan Eftekhari
- Department of Clinical Nutrition, School of Nutrition and Food SciencesShiraz University of Medical SciencesShirazIran
| |
Collapse
|
2
|
Chen C, Gao K, Chen Z, Zhang Q, Ke X, Mao B, Fan Q, Li Y, Chen S. The supplementation of the multi-strain probiotics WHHPRO™ alleviates high-fat diet-induced metabolic symptoms in rats via gut-liver axis. Front Nutr 2024; 10:1324691. [PMID: 38274203 PMCID: PMC10808617 DOI: 10.3389/fnut.2023.1324691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2023] [Accepted: 12/27/2023] [Indexed: 01/27/2024] Open
Abstract
Metabolic syndrome (MS) has emerged as one of the major global health concerns, accompanied by a series of related complications, such as obesity and type-2 diabetes. The gut-liver axis (GLA) is a bidirectional communication between the gut and the liver. The GLA alterations have been revealed to be closely associated with the development of MS. Probiotics within Lactobacillus and Bifidobacterium confer beneficial effects on improving MS symptoms. WHHPRO™ is a mixture of four probiotic strains, with potential MS-improving abilities. This study aimed to investigate the effects of WHHPRO™ on MS symptoms using a high-fat diet (HFD) rat model. Oral administration of WHHPRO™ for 12 weeks improved glucose tolerance, blood lipid, body weight, and liver index in HFD rats. WHHPRO™ shaped the gut microbiome composition by increasing the abundance of Lactobacillus and Akkermansia and normalized the reduced SCFA levels in HFD rats. Besides, WHHPRO™ modulated the fecal bile acids (BAs) profile, with decreased levels of T-b-MCA and 12-KDCA and increased levels of LCA and ILCA. Meanwhile, WHHPRO™ increased total unconjugated BAs in feces and liver and reduced the accumulation of total hepatic BA pool size in HFD rats. Moreover, WHHPRO™ reversed the expression of genes associated with impaired BA metabolism signaling in the ileum and liver. Our findings suggest that WHHPRO™ exerted beneficial effects on improving MS symptoms, involving the modulation of the gut microbiome composition, SCFAs, and the FXR-FGF15 signaling along the GLA. Supplementation of WHHPRO™ may serve as a novel strategy for improving MS symptoms.
Collapse
Affiliation(s)
- Cailing Chen
- Key Laboratory of Food and Biological Engineering of Zhejiang Province, Hangzhou, China
- Research and Development Department, Hangzhou Wahaha Group Co., Ltd., Hangzhou, China
- Hangzhou Wahaha Technology Co., Ltd., Hangzhou, China
| | - Kan Gao
- Key Laboratory of Food and Biological Engineering of Zhejiang Province, Hangzhou, China
- Research and Development Department, Hangzhou Wahaha Group Co., Ltd., Hangzhou, China
- Hangzhou Wahaha Technology Co., Ltd., Hangzhou, China
| | - Zuoguo Chen
- Key Laboratory of Food and Biological Engineering of Zhejiang Province, Hangzhou, China
- Research and Development Department, Hangzhou Wahaha Group Co., Ltd., Hangzhou, China
- Hangzhou Wahaha Technology Co., Ltd., Hangzhou, China
| | - Qiwen Zhang
- Key Laboratory of Food and Biological Engineering of Zhejiang Province, Hangzhou, China
- Research and Development Department, Hangzhou Wahaha Group Co., Ltd., Hangzhou, China
- Hangzhou Wahaha Technology Co., Ltd., Hangzhou, China
| | - Xueqin Ke
- Key Laboratory of Food and Biological Engineering of Zhejiang Province, Hangzhou, China
- Research and Development Department, Hangzhou Wahaha Group Co., Ltd., Hangzhou, China
- Hangzhou Wahaha Technology Co., Ltd., Hangzhou, China
| | - Bingyong Mao
- School of Food Science and Technology, Jiangnan University, Wuxi, China
| | - Qiuling Fan
- Key Laboratory of Food and Biological Engineering of Zhejiang Province, Hangzhou, China
- Research and Development Department, Hangzhou Wahaha Group Co., Ltd., Hangzhou, China
- Hangzhou Wahaha Technology Co., Ltd., Hangzhou, China
| | - Yanjun Li
- Key Laboratory of Food and Biological Engineering of Zhejiang Province, Hangzhou, China
- Research and Development Department, Hangzhou Wahaha Group Co., Ltd., Hangzhou, China
- Hangzhou Wahaha Technology Co., Ltd., Hangzhou, China
| | - Su Chen
- Key Laboratory of Food and Biological Engineering of Zhejiang Province, Hangzhou, China
- Research and Development Department, Hangzhou Wahaha Group Co., Ltd., Hangzhou, China
- Hangzhou Wahaha Technology Co., Ltd., Hangzhou, China
| |
Collapse
|
3
|
Balakumar P, Venkatesan K, Abdulla Khan N, Raghavendra NM, Venugopal V, Bharathi DR, Fuloria NK. Mechanistic insights into the beneficial effects of curcumin on insulin resistance: opportunities and challenges. Drug Discov Today 2023:103627. [PMID: 37224995 DOI: 10.1016/j.drudis.2023.103627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 05/03/2023] [Accepted: 05/17/2023] [Indexed: 05/26/2023]
Abstract
The past couple of decades in particular have seen a rapid increase in the prevalence of type 2 diabetes mellitus (T2DM), a debilitating metabolic disorder characterised by insulin resistance. The insufficient efficacy of current management strategies for insulin resistance calls for additional therapeutic options. The preponderance of evidence suggests potential beneficial effects of curcumin on insulin resistance, while modern science provides a scientific basis for its potential applications against the disease. Curcumin combats insulin resistance by increasing the levels of circulating irisin and adiponectin, activating PPARγ, suppressing Notch1 signalling, and regulating SREBP target genes, among others. In this review, we bring together the diverse areas pertaining to our current understanding of the potential benefits of curcumin on insulin resistance, associated mechanistic insights, and new therapeutic possibilities. Teaser: Current approaches to manage insulin resistance are not highly efficacious, which necessitates additional therapeutic options; curcumin combats insulin resistance by improving the levels of circulating irisin and adiponectin, upregulating and activating PPARγ, and suppressing Notch‑1 signalling.
Collapse
Affiliation(s)
- Pitchai Balakumar
- The Office of Research and Development, Periyar Maniammai Institute of Science & Technology, Vallam, Thanjavur 613 403, Tamil Nadu, India.
| | - Kumar Venkatesan
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Al-Qara, Abha 61421, Saudi Arabia
| | - Noohu Abdulla Khan
- Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Al-Qara, Abha 61421, Saudi Arabia
| | - N M Raghavendra
- Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru 560 111, India
| | - Vijayan Venugopal
- School of Pharmacy, Sri Balaji Vidyapeeth Deemed-to-be University, Puducherry 607 402, India
| | - D R Bharathi
- Department of Pharmacology, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B G Nagara, Nagamangala 571 448, India
| | - Neeraj K Fuloria
- Pharmaceutical Chemistry Unit, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Malaysia
| |
Collapse
|
4
|
Yamaoka S, Sasaki K, Sato S. Curcumin intake during lactation suppresses oxidative stress through upregulation of nuclear factor erythroid 2-related factor 2 in the kidneys of fructose-loaded female rat offspring exposed to maternal protein restriction. Birth Defects Res 2023; 115:674-686. [PMID: 36811147 DOI: 10.1002/bdr2.2158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Revised: 12/30/2022] [Accepted: 01/23/2023] [Indexed: 02/24/2023]
Abstract
BACKGROUND A high-fructose diet causes the progression of chronic kidney disease. Maternal malnutrition during pregnancy and lactation increases oxidative stress, leading to chronic renal diseases later in life. We investigated whether curcumin intake during lactation could suppress oxidative stress and regulate NF-E2-related factor 2 (Nrf2) expression in the kidneys of fructose-loaded female rat offspring exposed to maternal protein restriction. METHODS Pregnant Wistar rats received diets containing 20% (NP) or 8% (LP) casein and 0 or 2.5 g "highly absorptive curcumin" /kg diet containing-LP diets (LP/LP or LP/Cur) during lactation. At weaning, female offspring received either distilled water (W) or 10% fructose solution (Fr) and were divided into four groups: NP/NP/W, LP/LP/W, LP/LP/Fr, and LP/Cur/Fr. At week 13, glucose (Glc), triacylglycerol (Tg), and malondialdehyde (MDA) levels in the plasma, macrophages number, fibrotic area, glutathione (GSH) levels, glutathione peroxidase (GPx) activity, protein expression levels of Nrf2, heme oxygenase-1 (HO-1), and superoxide dismutase 1 (SOD1) in the kidneys were examined. RESULTS The plasma levels of Glc, TG, and MDA, the number of macrophages, and the percentage of fibrotic area in the kidneys of the LP/Cur/Fr group were significantly lower than those of the LP/LP/Fr group. The expression of Nrf2 and its downstream molecules HO-1 and SOD1, GSH levels, and GPx activity in the kidneys of the LP/Cur/Fr group were significantly higher than those of the LP/LP/Fr group. CONCLUSIONS Maternal curcumin intake during lactation may suppress oxidative stress by upregulating Nrf2 expression in the kidneys of fructose-loaded female offspring exposed to maternal protein restriction.
Collapse
Affiliation(s)
- Shin Yamaoka
- Aomori University of Health and Welfare, Graduate School of Health Sciences, Aomori, Japan.,Department of Nutrition, Akita Nutrition Junior College, Akita, Japan
| | - Kotomi Sasaki
- Department of Nutrition, Aomori University of Health and Welfare, Aomori, Japan
| | - Shin Sato
- Aomori University of Health and Welfare, Graduate School of Health Sciences, Aomori, Japan.,Department of Nutrition, Aomori University of Health and Welfare, Aomori, Japan
| |
Collapse
|
5
|
Zhao L, Shen Y, Wang Y, Wang L, Zhang L, Zhao Z, Li S. Lactobacillus plantarum S9 alleviates lipid profile, insulin resistance, and inflammation in high-fat diet-induced metabolic syndrome rats. Sci Rep 2022; 12:15490. [PMID: 36109620 PMCID: PMC9478128 DOI: 10.1038/s41598-022-19839-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Accepted: 09/05/2022] [Indexed: 11/25/2022] Open
Abstract
Probiotics are considered to play an crucial role in the treatment of high-fat diet (HFD)-induced lipid metabolic diseases, including metabolic syndrome (MS). This study aimed to investigate the effects of Lactobacillus plantarum S9 on MS in HFD-fed rats, and to explore the underlying role of probiotics in the treatment of MS. Sprague-Dawley rats were fed with HFD for 8 weeks, followed by the treatment of L. plantarum S9 for 6 weeks, and The body weight and blood glucose level of rats were detected on time. The results showed that L. plantarum S9 significantly decreased the body weight gain, Lee’s index, and liver index. Additionally, L. plantarum S9 reduced the levels of serum lipids and insulin resistance. L. plantarum S9 also decreased the levels of alanine aminotransferase (ALT) and aspartate transaminase (AST) in liver. Moreover, the serum levels of MS-related inflammatory signaling molecules, including lipopolysaccharide (LPS) and tumor necrosis factor-α (TNF-α), were significantly elevated. Western blot analysis showed that L. plantarum S9 inhibited the activation of nuclear factor-κB (NF-κB) pathway, decreased the expression level of Toll-like receptor 4 (TLR4), suppressed the activation of inflammatory signaling pathways, and reduced the expression levels of inflammatory factors in HFD-fed rats. Moreover, it further decreased the ratios of p-IκBα/IκBα, p-p65/NF-κB p65, and p-p38/p38. In summary, L. plantarum S9, as a potential functional strain, prevents or can prevent onset of MS.
Collapse
|
6
|
Hussain Y, Khan H, Alotaibi G, Khan F, Alam W, Aschner M, Jeandet P, Saso L. How Curcumin Targets Inflammatory Mediators in Diabetes: Therapeutic Insights and Possible Solutions. Molecules 2022; 27:4058. [PMID: 35807304 PMCID: PMC9268477 DOI: 10.3390/molecules27134058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2022] [Revised: 06/14/2022] [Accepted: 06/20/2022] [Indexed: 12/15/2022] Open
Abstract
Diabetes mellitus is a multifactorial chronic metabolic disorder, characterized by altered metabolism of macro-nutrients, such as fats, proteins, and carbohydrates. Diabetic retinopathy, diabetic cardiomyopathy, diabetic encephalopathy, diabetic periodontitis, and diabetic nephropathy are the prominent complications of diabetes. Inflammatory mediators are primarily responsible for these complications. Curcumin, a polyphenol derived from turmeric, is well known for its anti-oxidant, anti-inflammatory, and anti-apoptotic properties. The regulation of several signaling pathways effectively targets inflammatory mediators in diabetes. Curcumin’s anti-inflammatory and anti-oxidative activities against a wide range of molecular targets have been shown to have therapeutic potential for a variety of chronic inflammatory disorders, including diabetes. Curcumin’s biological examination has shown that it is a powerful anti-oxidant that stops cells from growing by releasing active free thiol groups at the target location. Curcumin is a powerful anti-inflammatory agent that targets inflammatory mediators in diabetes, and its resistant form leads to better therapeutic outcomes in diabetes complications. Moreover, Curcumin is an anti-oxidant and NF-B inhibitor that may be useful in treating diabetes. Curcumin has been shown to inhibit diabetes-related enzymes, such as a-glucosidase, aldose reductase and aldose reductase inhibitors. Through its anti-oxidant and anti-inflammatory effects, and its suppression of vascular endothelial development and nuclear transcription factors, curcumin has the ability to prevent, or reduce, the course of diabetic retinopathy. Curcumin improves insulin sensitivity by suppressing phosphorylation of ERK/JNK in HG-induced insulin-resistant cells and strengthening the PI3K-AKT-GSK3B signaling pathway. In the present article, we aimed to discuss the anti-inflammatory mechanisms of curcumin in diabetes regulated by various molecular signaling pathways.
Collapse
|
7
|
Méndez-García LA, Bueno-Hernández N, Cid-Soto MA, De León KL, Mendoza-Martínez VM, Espinosa-Flores AJ, Carrero-Aguirre M, Esquivel-Velázquez M, León-Hernández M, Viurcos-Sanabria R, Ruíz-Barranco A, Cota-Arce JM, Álvarez-Lee A, De León-Nava MA, Meléndez G, Escobedo G. Ten-Week Sucralose Consumption Induces Gut Dysbiosis and Altered Glucose and Insulin Levels in Healthy Young Adults. Microorganisms 2022; 10:microorganisms10020434. [PMID: 35208888 PMCID: PMC8880058 DOI: 10.3390/microorganisms10020434] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/03/2022] [Accepted: 02/09/2022] [Indexed: 02/04/2023] Open
Abstract
Sucralose consumption alters microbiome and carbohydrate metabolism in mouse models. However, there are no conclusive studies in humans. Our goals were to examine the effect of sucralose consumption on the intestinal abundance of bacterial species belonging to Actinobacteria, Bacteroidetes, and Firmicutes and explore potential associations between microbiome profiles and glucose and insulin blood levels in healthy young adults. In this open-label clinical trial, volunteers randomly drank water, as a control (n = 20), or 48 mg sucralose (n = 20), every day for ten weeks. At the beginning and the end of the study, participants were subjected to an oral glucose tolerance test (OGTT) to measure serum glucose and insulin every 15 min for 3 h and provided fecal samples to assess gut microbiota using a quantitative polymerase chain reaction. Sucralose intake altered the abundance of Firmicutes without affecting Actinobacteria or Bacteroidetes. Two-way ANOVA revealed that volunteers drinking sucralose for ten weeks showed a 3-fold increase in Blautia coccoides and a 0.66-fold decrease in Lactobacillus acidophilus compared to the controls. Sucralose consumption increased serum insulin and the area under the glucose curve compared to water. Long-term sucralose ingestion induces gut dysbiosis associated with altered insulin and glucose levels during an OGTT.
Collapse
Affiliation(s)
- Lucía A. Méndez-García
- Laboratory of Immunometabolism, Research Division, General Hospital of Mexico, Mexico City 06720, Mexico; (L.A.M.-G.); (R.V.-S.)
| | - Nallely Bueno-Hernández
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Miguel A. Cid-Soto
- Immunogenomics and Metabolic Diseases Laboratory, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico;
| | - Karen L. De León
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Viridiana M. Mendoza-Martínez
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Aranza J. Espinosa-Flores
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Miguel Carrero-Aguirre
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Marcela Esquivel-Velázquez
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Mireya León-Hernández
- Laboratory for Proteomics and Metabolomics, General Hospital of Mexico, Mexico City 06720, Mexico; (N.B.-H.); (K.L.D.L.); (V.M.M.-M.); (A.J.E.-F.); (M.C.-A.); (M.E.-V.); (M.L.-H.)
| | - Rebeca Viurcos-Sanabria
- Laboratory of Immunometabolism, Research Division, General Hospital of Mexico, Mexico City 06720, Mexico; (L.A.M.-G.); (R.V.-S.)
- PECEM, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
| | | | - Julián M. Cota-Arce
- Department of Biomedical Innovation, Center for Scientific Research and Higher Education of Ensenada (CICESE), Baja California 22860, Mexico; (J.M.C.-A.); (A.Á.-L.); (M.A.D.L.-N.)
| | - Angélica Álvarez-Lee
- Department of Biomedical Innovation, Center for Scientific Research and Higher Education of Ensenada (CICESE), Baja California 22860, Mexico; (J.M.C.-A.); (A.Á.-L.); (M.A.D.L.-N.)
| | - Marco A. De León-Nava
- Department of Biomedical Innovation, Center for Scientific Research and Higher Education of Ensenada (CICESE), Baja California 22860, Mexico; (J.M.C.-A.); (A.Á.-L.); (M.A.D.L.-N.)
| | - Guillermo Meléndez
- Facultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo León, Monterrey 64460, Mexico
- Correspondence: (G.M.); (G.E.); Tel.: +52-552-789-2000 (ext. 5646) (G.E.)
| | - Galileo Escobedo
- Laboratory of Immunometabolism, Research Division, General Hospital of Mexico, Mexico City 06720, Mexico; (L.A.M.-G.); (R.V.-S.)
- Correspondence: (G.M.); (G.E.); Tel.: +52-552-789-2000 (ext. 5646) (G.E.)
| |
Collapse
|
8
|
Hussain Y, Islam L, Khan H, Filosa R, Aschner M, Javed S. Curcumin-cisplatin chemotherapy: A novel strategy in promoting chemotherapy efficacy and reducing side effects. Phytother Res 2021; 35:6514-6529. [PMID: 34347326 DOI: 10.1002/ptr.7225] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 06/08/2021] [Accepted: 07/12/2021] [Indexed: 12/13/2022]
Abstract
The efficacy of chemotherapy in cancer therapy is limited due to resistance, treatment selectivity, and severe adverse effects. Immunotherapy, chemotherapy, targeted therapy, radiation, and surgery are the most common therapeutic strategies for treatment, with chemotherapy being the most successful. Nonetheless, these treatments exhibit poor effectiveness due to toxicity and resistance. Therefore, combination therapies of natural products may be used as an effective and novel strategy to overcome such barriers. Cisplatin is a platinum-based chemotherapy agent, and when administered alone, it can lead to severe adverse effects and resistance mechanism resulting in therapeutic failure. Curcumin is a polyphenolic compound extracted from turmeric (Curcuma longa) exhibiting anticancer potential with minimal adverse effects. The combination therapy of curcumin and cisplatin is a novel strategy to mitigate/attenuate cisplatin-related adverse effects and improve the barrier of resistance reducing unwanted effects. However, there are uncertainties on the efficacy of curcumin, and more in depth and high-quality studies are needed. This review aims to explain the adverse effects related to individual cisplatin delivery, the positive outcome of individual curcumin delivery, and the combination therapy of curcumin and cisplatin from nano platform as a novel strategy for cancer therapy.
Collapse
Affiliation(s)
- Yaseen Hussain
- Lab of Controlled Release and Drug Delivery System, College of Pharmaceutical Sciences, Soochow University, Suzhou, China
- Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan
| | - Lubna Islam
- Department of Pharmacy, University of Malakand, Dir Lower Chakdara, KPK, Pakistan
| | - Haroon Khan
- Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan
| | - Rosanna Filosa
- Department of Experimental Medicine, University of Campania, "L. Vanvitelli", Naples, Italy
| | - Michael Aschner
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Saba Javed
- Department of Zoology, Hazara University, Mansehra, Pakistan
| |
Collapse
|
9
|
Gawlik-Kotelnicka O, Strzelecki D. Probiotics as a Treatment for "Metabolic Depression"? A Rationale for Future Studies. Pharmaceuticals (Basel) 2021; 14:ph14040384. [PMID: 33924064 PMCID: PMC8074252 DOI: 10.3390/ph14040384] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 04/16/2021] [Accepted: 04/18/2021] [Indexed: 02/06/2023] Open
Abstract
Depression and metabolic diseases often coexist, having several features in common, e.g., chronic low-grade inflammation and intestinal dysbiosis. Different microbiota interventions have been proposed to be used as a treatment for these disorders. In the paper, we review the efficacy of probiotics in depressive disorders, obesity, metabolic syndrome and its liver equivalent based on the published experimental studies, clinical trials and meta-analyses. Probiotics seem to be effective in reducing depressive symptoms when administered in addition to antidepressants. Additionally, probiotics intake may ameliorate some of the clinical components of metabolic diseases. However, standardized methodology regarding probiotics use in clinical trials has not been established yet. In this narrative review, we discuss current knowledge on the recently used methodology with its strengths and limitations and propose criteria that may be implemented to create a new study of the effectiveness of probiotics in depressive disorders comorbid with metabolic abnormalities. We put across our choice on type of study population, probiotics genus, strains, dosages and formulations, intervention period, as well as primary and secondary outcome measures.
Collapse
|